QUOTE AND NEWS
Benzinga  Dec 5  Comment 
HC Wainwright has started coverage of The Medicines Company (NASDAQ: MDCO) with a Buy rating and $57 price target on the back of Phase 3-ready inclisiran (PCSK9si). Key Catalyst: Inclisiran Inclisiran is an RNAi therapeutic that inhibits...
Benzinga  Dec 5  Comment 
  Analysts at HSBC initiated coverage of Morgan Stanley (NYSE: MS) with a Hold rating. The price target for Morgan Stanley is set to $42. Morgan Stanley shares closed at $41.83 on Friday. Analysts at Credit Suisse assumed coverage on ...
FierceBiotech  Nov 8  Comment 
The Medicines Company drops MDCO-216 as med comes up short badams Tue, 11/08/2016 - 03:51
Motley Fool  Oct 6  Comment 
The drugmaker gets infected by problems with its partner's program.




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki